H.C. Wainwright analyst Douglas Tsao raised his price target for Dermira to $22 from $13 saying the company last week announced "very strong" data from the Phase 2B Treble study for lebrikizumab in the treatment of atopic dermatitis. The data arguably represents a "best case" scenario for Dermira, Tsao tells investors in a research note. The results were "sufficiently compelling to put to rest any debate" whether the company should move into lebrikizumab into Phase 3 testing, contends the analyst. He raised his peak sales estimate for lebrikizumab to $2.5B, up from $1.5B, and keeps a Buy rating on Dermira.